Precision Oncology Outlook: Peptide-Receptor & Antibody-Radionuclide Conjugates for Personalized
公開 2026/04/03 10:36
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Integrated Radionuclide Medicine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Integrated Radionuclide Medicine market, including market size, share, demand, industry development status, and forecasts for the next few years.
For nuclear medicine physicians, oncologists, and radiopharmaceutical developers, the ability to both image and treat cancer using the same targeting molecule—a "theranostic" approach—represents a paradigm shift in precision oncology. The global Integrated Radionuclide Medicine market addresses this need through radiopharmaceutical systems that combine radionuclides with targeting molecules (peptides, antibodies, small molecule ligands) via chemical linkage, resulting in both diagnostic and therapeutic capabilities. These drugs leverage the high affinity and selectivity of targeting molecules for specific lesions (tumor cells) to precisely deliver radionuclides to affected areas, achieving integration of targeted imaging and targeted therapy. With advantages including high specificity, low toxicity, and personalized treatment capabilities, these drugs are becoming a key convergence area between precision medicine and nuclear medicine.
The global market for Integrated Radionuclide Medicine was estimated to be worth US$ 1436 million in 2025 and is projected to reach US$ 3360 million, growing at a CAGR of 13.1% from 2026 to 2032. This robust growth reflects the expanding adoption of theranostic approaches in oncology.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6093675/integrated-radionuclide-medicine
Theranostic Radiopharmaceuticals for Precision Oncology
Integrated radionuclide drugs are radiopharmaceutical systems that combine radionuclides with targeting molecules (such as peptides, antibodies, and small molecule ligands) through chemical linkage, resulting in both diagnostic and therapeutic capabilities. These drugs leverage the high affinity and selectivity of targeting molecules for specific lesions (such as tumor cells) to precisely deliver the radionuclide to the affected area, achieving the integration of "targeted imaging and targeted therapy," a so-called "theranostics" model. With advantages such as high specificity, low toxicity and side effects, and the ability to personalize treatment, these drugs are becoming a key area of convergence between precision medicine and nuclear medicine.
The theranostic pair concept uses one isotope for imaging (e.g., 68Ga, 64Cu) and another for therapy (e.g., 177Lu, 225Ac, 90Y) targeting the same biomarker. Well-established examples include 68Ga/177Lu-DOTATATE for neuroendocrine tumors (NETs) and 68Ga/177Lu-PSMA for prostate cancer. Patient selection via diagnostic imaging enables personalized therapy, reducing unnecessary treatment and improving outcomes.
Industry Segmentation: Drug Types & Applications
The Integrated Radionuclide Medicine market is segmented by product type and end-use industry:
Diagnostic Radionuclide Drugs: Imaging agents for patient selection and treatment monitoring (68Ga-DOTATATE, 68Ga-PSMA-11). A leading cancer center reported that diagnostic imaging with 68Ga-PSMA identified prostate cancer metastases missed by conventional imaging in 30% of patients.
Integrated Diagnostic and Therapeutic Radionuclide Drugs: Theranostic pairs where the same targeting molecule is labeled with diagnostic and therapeutic isotopes. 177Lu-DOTATATE (Lutathera) is FDA-approved for neuroendocrine tumors; 177Lu-PSMA-617 (Pluvicto) is FDA-approved for metastatic castration-resistant prostate cancer.
Application Segments
Healthcare Industry: Hospital-based nuclear medicine and radiation oncology departments administering theranostic radiopharmaceuticals.
Nuclear Medicine Industry: Radiopharmacies and cyclotron facilities producing and distributing radionuclides and finished products.
Biomedical Research and Development Industry: Academic and industry R&D for novel targets, isotopes, and conjugates.
Others: CROs and CDMOs offering radiolabeling and development services.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Alpha-emitting isotopes (225Ac, 212Pb) for therapy are gaining traction for treatment-resistant cancers. Novel targeting vectors (FAP inhibitors, integrin ligands) are expanding beyond PSMA and SSTR targets. Radiolabeled antibody-drug conjugates combine targeted delivery with potent payloads.
The trend toward decentralized radiopharmacy and on-site synthesis supports rapid distribution of short-half-life isotopes. Combination therapy with checkpoint inhibitors is being explored. Supply chain security for medical isotopes (177Lu, 225Ac, 68Ga) remains a critical industry focus.
Regional Market Dynamics
North America leads the integrated radionuclide medicine market, driven by FDA approvals (Lutathera, Pluvicto), strong radiopharmacy infrastructure, and reimbursement for theranostic procedures. The United States dominates with significant clinical adoption.
Europe follows closely, with strong nuclear medicine tradition in Germany, France, and the Netherlands, and EMA approvals. Asia-Pacific is the fastest-growing region, with expanding nuclear medicine infrastructure, increasing cancer incidence, and government support in China, Japan, South Korea, and Australia.
Competitive Landscape
Key players include Novartis, Bayer AG, Curium, ITM Radiopharma, POINT Biopharma Global, Lantheus Holdings, Clarity Pharmaceuticals, RadioMedix, Telix Pharmaceuticals, ARTBIO, RayzeBio, Convergent Therapeutics, Mariana Oncology, Ratio Therapeutics, Advanced Accelerator Applications, Cardinal Health, GE HealthCare, Jubilant Pharma, IRE ELiT, NTP Radioisotopes, China Isotope & Radiation, Yantai Dongcheng Biochemicals, Beijing Sinotau International Pharmaceutical Technology, Hexin Pharmaceutical Technology, and Fulian Pharmaceuticals.
Market Segmentation
The Integrated Radionuclide Medicine market is segmented as below:
By Company
Novartis
Bayer AG
Curium
ITM Radiopharma
POINT Biopharma Global
Lantheus Holdings
Clarity Pharmaceuticals
RadioMedix
Telix Pharmaceuticals
ARTBIO
RayzeBio
Convergent Therapeutics
Mariana Oncology
Ratio Therapeutics
Advanced Accelerator Applications
Cardinal Health
GE HealthCare
Jubilant Pharma
IRE ELiT
NTP Radioisotopes
China Isotope & Radiation
Yantai Dongcheng Biochemicals
Beijing Sinotau International Pharmaceutical Technology
Hexin Pharmaceutical Technology
Fulian Pharmaceuticals
Segment by Type
Diagnostic Radionuclide Drugs
Integrated Diagnostic and Therapeutic Radionuclide Drugs
Segment by Application
Healthcare Industry
Nuclear Medicine Industry
Biomedical Research and Development Industry
Others
Exclusive Industry Outlook
Looking ahead, the convergence of integrated radionuclide medicine technology with novel targets, alpha-emitting isotopes, and combination therapies represents a transformative growth opportunity. Development of theranostic pairs for additional cancer types (breast, lung, pancreatic, ovarian) will expand addressable markets. Novel isotopes (161Tb, 67Cu) with improved properties are entering clinical development. Integration with immuno-oncology (radiopharmaceuticals + checkpoint inhibitors) may enhance efficacy. Additionally, the expansion of radiopharmaceutical manufacturing capacity and supply chains will enable broader patient access. The ability to offer integrated radionuclide medicines that combine target specificity, favorable biodistribution, and clinical efficacy—supported by robust manufacturing and distribution—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For nuclear medicine physicians, oncologists, and radiopharmaceutical developers, the ability to both image and treat cancer using the same targeting molecule—a "theranostic" approach—represents a paradigm shift in precision oncology. The global Integrated Radionuclide Medicine market addresses this need through radiopharmaceutical systems that combine radionuclides with targeting molecules (peptides, antibodies, small molecule ligands) via chemical linkage, resulting in both diagnostic and therapeutic capabilities. These drugs leverage the high affinity and selectivity of targeting molecules for specific lesions (tumor cells) to precisely deliver radionuclides to affected areas, achieving integration of targeted imaging and targeted therapy. With advantages including high specificity, low toxicity, and personalized treatment capabilities, these drugs are becoming a key convergence area between precision medicine and nuclear medicine.
The global market for Integrated Radionuclide Medicine was estimated to be worth US$ 1436 million in 2025 and is projected to reach US$ 3360 million, growing at a CAGR of 13.1% from 2026 to 2032. This robust growth reflects the expanding adoption of theranostic approaches in oncology.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6093675/integrated-radionuclide-medicine
Theranostic Radiopharmaceuticals for Precision Oncology
Integrated radionuclide drugs are radiopharmaceutical systems that combine radionuclides with targeting molecules (such as peptides, antibodies, and small molecule ligands) through chemical linkage, resulting in both diagnostic and therapeutic capabilities. These drugs leverage the high affinity and selectivity of targeting molecules for specific lesions (such as tumor cells) to precisely deliver the radionuclide to the affected area, achieving the integration of "targeted imaging and targeted therapy," a so-called "theranostics" model. With advantages such as high specificity, low toxicity and side effects, and the ability to personalize treatment, these drugs are becoming a key area of convergence between precision medicine and nuclear medicine.
The theranostic pair concept uses one isotope for imaging (e.g., 68Ga, 64Cu) and another for therapy (e.g., 177Lu, 225Ac, 90Y) targeting the same biomarker. Well-established examples include 68Ga/177Lu-DOTATATE for neuroendocrine tumors (NETs) and 68Ga/177Lu-PSMA for prostate cancer. Patient selection via diagnostic imaging enables personalized therapy, reducing unnecessary treatment and improving outcomes.
Industry Segmentation: Drug Types & Applications
The Integrated Radionuclide Medicine market is segmented by product type and end-use industry:
Diagnostic Radionuclide Drugs: Imaging agents for patient selection and treatment monitoring (68Ga-DOTATATE, 68Ga-PSMA-11). A leading cancer center reported that diagnostic imaging with 68Ga-PSMA identified prostate cancer metastases missed by conventional imaging in 30% of patients.
Integrated Diagnostic and Therapeutic Radionuclide Drugs: Theranostic pairs where the same targeting molecule is labeled with diagnostic and therapeutic isotopes. 177Lu-DOTATATE (Lutathera) is FDA-approved for neuroendocrine tumors; 177Lu-PSMA-617 (Pluvicto) is FDA-approved for metastatic castration-resistant prostate cancer.
Application Segments
Healthcare Industry: Hospital-based nuclear medicine and radiation oncology departments administering theranostic radiopharmaceuticals.
Nuclear Medicine Industry: Radiopharmacies and cyclotron facilities producing and distributing radionuclides and finished products.
Biomedical Research and Development Industry: Academic and industry R&D for novel targets, isotopes, and conjugates.
Others: CROs and CDMOs offering radiolabeling and development services.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Alpha-emitting isotopes (225Ac, 212Pb) for therapy are gaining traction for treatment-resistant cancers. Novel targeting vectors (FAP inhibitors, integrin ligands) are expanding beyond PSMA and SSTR targets. Radiolabeled antibody-drug conjugates combine targeted delivery with potent payloads.
The trend toward decentralized radiopharmacy and on-site synthesis supports rapid distribution of short-half-life isotopes. Combination therapy with checkpoint inhibitors is being explored. Supply chain security for medical isotopes (177Lu, 225Ac, 68Ga) remains a critical industry focus.
Regional Market Dynamics
North America leads the integrated radionuclide medicine market, driven by FDA approvals (Lutathera, Pluvicto), strong radiopharmacy infrastructure, and reimbursement for theranostic procedures. The United States dominates with significant clinical adoption.
Europe follows closely, with strong nuclear medicine tradition in Germany, France, and the Netherlands, and EMA approvals. Asia-Pacific is the fastest-growing region, with expanding nuclear medicine infrastructure, increasing cancer incidence, and government support in China, Japan, South Korea, and Australia.
Competitive Landscape
Key players include Novartis, Bayer AG, Curium, ITM Radiopharma, POINT Biopharma Global, Lantheus Holdings, Clarity Pharmaceuticals, RadioMedix, Telix Pharmaceuticals, ARTBIO, RayzeBio, Convergent Therapeutics, Mariana Oncology, Ratio Therapeutics, Advanced Accelerator Applications, Cardinal Health, GE HealthCare, Jubilant Pharma, IRE ELiT, NTP Radioisotopes, China Isotope & Radiation, Yantai Dongcheng Biochemicals, Beijing Sinotau International Pharmaceutical Technology, Hexin Pharmaceutical Technology, and Fulian Pharmaceuticals.
Market Segmentation
The Integrated Radionuclide Medicine market is segmented as below:
By Company
Novartis
Bayer AG
Curium
ITM Radiopharma
POINT Biopharma Global
Lantheus Holdings
Clarity Pharmaceuticals
RadioMedix
Telix Pharmaceuticals
ARTBIO
RayzeBio
Convergent Therapeutics
Mariana Oncology
Ratio Therapeutics
Advanced Accelerator Applications
Cardinal Health
GE HealthCare
Jubilant Pharma
IRE ELiT
NTP Radioisotopes
China Isotope & Radiation
Yantai Dongcheng Biochemicals
Beijing Sinotau International Pharmaceutical Technology
Hexin Pharmaceutical Technology
Fulian Pharmaceuticals
Segment by Type
Diagnostic Radionuclide Drugs
Integrated Diagnostic and Therapeutic Radionuclide Drugs
Segment by Application
Healthcare Industry
Nuclear Medicine Industry
Biomedical Research and Development Industry
Others
Exclusive Industry Outlook
Looking ahead, the convergence of integrated radionuclide medicine technology with novel targets, alpha-emitting isotopes, and combination therapies represents a transformative growth opportunity. Development of theranostic pairs for additional cancer types (breast, lung, pancreatic, ovarian) will expand addressable markets. Novel isotopes (161Tb, 67Cu) with improved properties are entering clinical development. Integration with immuno-oncology (radiopharmaceuticals + checkpoint inhibitors) may enhance efficacy. Additionally, the expansion of radiopharmaceutical manufacturing capacity and supply chains will enable broader patient access. The ability to offer integrated radionuclide medicines that combine target specificity, favorable biodistribution, and clinical efficacy—supported by robust manufacturing and distribution—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ